After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

The Seoul Central District Court ruled against Regeneron, which had sought to block Samsung Bioepis from producing and selling a biosimilar referencing the US firm’s Eylea, a blockbuster medicine used ...

Regeneron (NASDAQ: REGN) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its previous ...

A recent U.S. Court of Appeals decision has implications not only for companies in health care, but for any organization ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...